Human epididymis protein 4 (HE4) and ovarian cancer prognosis

Gynecologic Oncology

Volumn 127, Issue 3, 2012, Pages 511-515

  Trudel, Dominique ^a,b   Têtu, Bernard ^a   Grégoire, Jean ^a   Plante, Marie ^a   Renaud, Marie Claude ^a   Bachvarov, Dimcho ^a   Douville, Pierre ^a   Bairati, Isabelle ^a,c  

^a LAVAL UNIVERSITY   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

HE4; Human epididymis protein 4; Mortality; Ovarian cancer; Progression; Survival

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; HUMAN EPIDIDYMIS PROTEIN 4; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANADA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; CA-125 ANTIGEN; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROTEINS; RETROSPECTIVE STUDIES;

EID: 84868609395     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.09.003     Document Type: Article

References (26)

1. J. Permuth-Wey, and T.A. Sellers Epidemiology of ovarian cancer Methods Mol Biol 472 2009 413 437
2. A.P. Heintz, F. Odicino, P. Maisonneuve, M.A. Quinn, J.L. Benedet, and W.T. Creasman Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer Int J Gynaecol Obstet 95 Suppl. 1 2006 (S161-92.:S161-S92)
3. A. du Bois, J. Herrstedt, A.C. Hardy-Bessard, H.H. Muller, P. Harter, and G. Kristensen Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer J Clin Oncol 28 27 Sep 20 2010 4162 4169
4. S. Pecorelli, B. Pasinetti, G. Tisi, L. Zigliani, F.E. Odicino, and L.H. Sobin Ovarian and fallopian tube cancer TNM online 2006 John Wiley & Sons, Inc.
5. Clinical Practice guidelines in Oncology Ovarian cancer including fallopian tube cancer and primary peritoneal cancer 2006 (www.nccn.com)
6. A. du Bois, M. Quinn, T. Thigpen, J. Vermorken, E. Avall-Lundqvist, and M. Bookman Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 Suppl. 8 2005 viii7 viii12
7. A. Clauss, H. Lilja, and A. Lundwall A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein Biochem J 368 Pt 1 Nov 15 2002 233 242
8. J. Li, S. Dowdy, T. Tipton, K. Podratz, W.G. Lu, and X. Xie HE4 as a biomarker for ovarian and endometrial cancer management Expert Rev Mol Diagn 9 6 2009 555 566
9. K. Huhtinen, P. Suvitie, J. Hiissa, J. Junnila, J. Huvila, and H. Kujari Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts Br J Cancer 100 8 2009 1315 1319
10. J.M. Escudero, J.M. Auge, X. Filella, A. Torne, J. Pahisa, and R. Molina Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases Clin Chem 57 11 Nov 2011 1534 1544
11. R.G. Moore, A.K. Brown, M.C. Miller, S. Skates, W.J. Allard, and T. Verch The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecol Oncol 108 2 Feb 2008 402 408
12. J. Paek, S.H. Lee, G.W. Yim, M. Lee, Y.J. Kim, and E.J. Nam Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer Eur J Obstet Gynecol Reprod Biol 158 2 Oct 2011 338 342
13. S.Y. Kong, M.H. Han, H.J. Yoo, J.H. Hwang, M.C. Lim, and S.S. Seo Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer Ann Surg Oncol 19 5 May 2012 1707 1712
14. E. Bandiera, C. Romani, C. Specchia, L. Zanotti, C. Galli, and G. Ruggeri Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management Cancer Epidemiol Biomarkers Prev 20 12 Dec 2011 2496 2506
15. S.G. Silverberg Histopathologic grading of ovarian carcinoma: a review and proposal Int J Gynecol Pathol 19 1 2000 7 15
16. I. Vergote, G.J. Rustin, E.A. Eisenhauer, G.B. Kristensen, E. Pujade-Lauraine, and M.K. Parmar Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup J Natl Cancer Inst 20 92(18) 2000 1534 1535
17. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
18. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Reporting recommendations for tumor marker prognostic studies J Clin Oncol 20 23(36) 2005 9067 9072
19. T.M. Therneau, and P.M. Grambsch Modeling survival data: extending the Cox model 2000 Springer
20. R. Simon, and D.G. Altman Statistical aspects of prognostic factor studies in oncology Br J Cancer 69 6 1994 979 985
21. T. Van Gorp, I. Cadron, E. Despierre, A. Daemen, K. Leunen, and F. Amant HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm Br J Cancer 104 5 Mar 1 2011 863 870
22. A.M. Oza, V. Castonguay, D. Tsoref, I. Diaz-Padilla, K. Karakasis, and H. Mackay Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective Curr Oncol 18 Suppl. 2 Oct 2011 S20 S27
23. W.G. McCluggage Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis Pathology 43 5 Aug 2011 420 432
24. R.C. Bast Jr., B. Hennessy, and G.B. Mills The biology of ovarian cancer: new opportunities for translation Nat Rev Cancer 9 6 2009 415 428
25. J.J. Han, M. Yu, N. Houston, S.M. Steinberg, and E.C. Kohn Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers Gynecol Oncol 120 1 Jan 2011 5 10
26. K.D. Steffensen, M. Waldstrom, I. Brandslund, and A. Jakobsen Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients Int J Gynecol Cancer 21 6 Aug 2011 1040 1047